Drugs / AT278
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05754424 | Feb 2023 → Jan 2024 | type 2 diabetes mellitus | Arecor Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-13 | Arecor Limited | Results Peer-Reviewed Publication of AT278 Study in Diabetes, Obesity and Metabolism journal arecor.com ↗
AT278 exhibited a significantly faster insulin absorption than both standard U100 concentration insulin aspart and U500 human regular insulin. |
| 2026-07-30 | Arecor Limited | Results Diabetes, Obesity and Metabolism article – A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI arecor.com ↗
A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05754424 ↗ |
| Known as | insulin aspart | “This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard...” NCT05754424 ↗ |
| Modality | Protein / enzyme biologic | “Concentrated rapid acting insulin aspart” NCT05754424 ↗ |
| Route | Subcutaneous | “Single subcutaneous injection of 0.5 U/kg” NCT05754424 ↗ |